Moreover, we provided evidence that LIFR inhibitor EC359 inhibited the growth of OCa cells in vitro and tumor progression in cell-derived xenografts (CDX) and patient-derived xenograft (PDX) models. This evidence concerns the gene LIFR and oculocutaneous albinism.